Arnold M, Rutherford MJ, Bardot A, et al. - Researchers undertook the Cancer Survival in High-Income Countries (SURVMARK-2) project as part of the second phase of the International Cancer Benchmarking Partnership, in order to present a comprehensive overview of cancer survival across seven high-income countries and a comparative estimation of corresponding incidence and mortality trends. They used population-based cancer registries in 21 jurisdictions in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the UK) for seven sites of cancer (oesophagus, stomach, colon, rectum, pancreas, lung, and ovary) diagnosed between 1995 and 2014, and followed up until Dec 31, 2015 and included 3,764,543 cases of cancer in the study. The analysis revealed progress in the joint evaluation of trends in incidence, mortality, and survival in four of the seven studied cancers. Despite a continuous increase in cancer survival across high-income countries; international disparities persisted. While minimal differences in registration practice, classification, and coding are required for truly valid comparisons, the main determinants of patient outcomes seem to be the stage of disease at diagnosis, timely access to effective treatment, and the extent of comorbidity.